Review Outlines Strategies for Kidney-Targeted Drug Delivery Systems
A February 2026 review analyzes strategies for kidney-targeted drug delivery systems, examining renal targeting mechanisms and nanocarrier platforms. The review highlights how functionalized nanoparticles can achieve enhanced renal specificity while addressing remaining translational challenges in the field.
A comprehensive review published in February 2026 provides a structured analysis of advanced strategies for engineering kidney-targeted drug delivery systems. The review examines fundamental mechanisms of renal targeting and deconstructs delivery systems into carrier platforms, functional moieties, and therapeutic cargo to offer a rational design framework for next-generation intelligent kidney-targeted therapeutics.
Kidney-targeted drug delivery is pivotal for treating renal diseases while minimizing systemic toxicity. To navigate the organ's complex physiological barriers, advanced nanomedicines employ integrated strategies. The review examines the fundamental mechanisms of renal targeting including passive filtration, active receptor-mediated uptake, and their synergistic combination.
The kidney is one of the most vital organs in the human body, playing important roles in maintaining internal environmental stability, excreting metabolic waste, and regulating various physiological processes. Dysfunction of the kidney will lead to many diseases, including renal tumor, kidney stone, acute kidney injury, chronic kidney disease, and diabetic nephropathy. Kidney disease is a significant global public health issue that has profound impacts on individuals, healthcare systems, and socioeconomic structures.
Drug therapy and surgical treatment are the two main treatments for kidney diseases. Drug therapy requires a certain concentration of drugs that eventually reach the kidney to be effective. Unfortunately, the kidney is a complex organ with many barriers, which make it hard to deliver to. The vascular endothelial cells within the kidneys form a sieve-like structure. The tight junctions between these cells restrict the passage of large molecules and highly polar substances, while small molecules and lipophilic drugs can pass through more easily.
As drugs pass through the glomerulus, they come into contact with the glomerular basement membrane. The selective filtration function of the basement membrane allows small molecule drugs to pass through, while large molecules or negatively charged drugs may be restricted by its filtration capacity. After drugs enter the renal tubular lumen, they might be reabsorbed across the tubular epithelial cells into the peritubular capillaries. These cells utilize both active transport and passive diffusion mechanisms.
Importantly, drug entry into renal tissues is not exclusively dependent on glomerular filtration. In addition to the luminal route, therapeutic agents can also access the kidney through the peritubular capillary network, which arises from post-glomerular efferent arterioles. Via this pathway, drugs and nanocarriers in the systemic circulation may directly interact with the basolateral membrane of tubular epithelial cells or renal interstitial compartments, providing an alternative and often dominant route for larger molecules, nanoparticles, and biologics.
The review evaluates how polymeric nanoparticles, liposomes, and exosomes, when functionalized with peptides, antibodies, or biomimetic coatings, can achieve enhanced renal specificity. Furthermore, it discusses how microenvironmental triggers such as pH, reactive oxygen species, and enzymes enable precise spatiotemporal drug release at pathological sites.
Despite significant progress, critical translational challenges remain, including overcoming hepatic sequestration, ensuring long-term biocompatibility, and addressing patient heterogeneity. Future advances will depend on combining multimodal targeting, real-time feedback, and scalable manufacturing processes.